Substantial weight regain occurred after treatment withdrawal in STEP 1 and SURMOUNT-4. Discuss ongoing treatment and any planned interruption with the prescriber before the last refill; the evidence does not prescribe a universal taper or require an annual subscription.
Read each percentage against its own reference weight.
Read the starting point before the percentage
The question is not simply whether a medicine produced weight loss. It is what happened after treatment was removed, who remained in the study and which weight measurement anchors the reported change. Those details decide whether two apparently similar percentages mean the same thing.
The STEP 1 extension followed a subset after semaglutide and structured lifestyle support ended. SURMOUNT-4 randomized people after a tirzepatide lead-in to continue medicine or switch to placebo. They answer related questions with different designs. Neither is a direct comparison between semaglutide and tirzepatide.[1] [2]
| Study | What changed | Interpretation boundary |
|---|---|---|
| STEP 1 extension | Treatment and structured lifestyle support ended at week 68 | Exploratory follow-up; no randomized continuation arm |
| SURMOUNT-4 | After 36 weeks, continue tirzepatide or switch to placebo | Randomized comparison among people completing the lead-in |
For a provider comparison, this distinction has an immediate use: ask what the service means by maintenance. It might mean continued prescribing, a clinical reassessment or a commercial subscription label. Those are not interchangeable promises. Ask which actual clinical services remain available and which payments continue.
What STEP 1 observed a year later
In the extension, 327 participants were followed. The semaglutide group had lost 17.3% by week 68, then regained 11.6 percentage points over the following year, leaving mean weight 5.6% below the original baseline. The authors characterized this as regaining about two-thirds of the earlier loss. Novo Nordisk funded the study.[1]
The denominator matters: percentage points of original body weight differ from the percentage of weight previously lost. Neither number says that everyone regained all their weight. An average combines different individual paths and cannot supply a forecast for a particular person.
Our interpretation is that a short course followed by effortless, permanent maintenance is a poor default budgeting assumption. That does not tell you whether continuing the same treatment is appropriate. Clinical benefit, adverse effects, preferences and access all belong in the follow-up conversation. It also does not mean the annual plan on a provider’s checkout page is medically necessary.
Compare ongoing obligations with the first-year cost calculator before choosing a commitment.
What randomized withdrawal adds
SURMOUNT-4 randomized 670 participants after a 36-week lead-in that produced mean weight loss of 20.9%. Over the next 52 weeks, continuing tirzepatide produced a further 5.5% reduction while switching to placebo produced a 14.0% increase. These changes use week-36 weight as their reference. Lilly funded the trial.[2]
Do not subtract these percentages directly from the earlier loss as though all use starting weight. A changed reference weight changes the calculation. The comparison also concerns people who reached randomization after the lead-in, not every person who might begin treatment in ordinary care.
Randomization strengthens the comparison between continuing and withdrawing within that studied group. It does not establish the best individualized transition, a preferred commercial provider or a universal treatment duration. The study’s prescription and supervision should not be silently transferred to a different compounded preparation or a seller’s maintenance protocol.
Separate medical continuity from contract length
A sustainable arrangement has two plans: what the clinical team will reassess, and what you can continue paying. Ask for the recurring treatment total after the introductory offer, including medicine, care and any necessary testing. Then ask what remains payable if the clinician changes the prescription or recommends stopping.
The Collective review examines an annual membership alongside monthly medicine payments. Our HealthRX review examines a different subscription and price-verification problem. Neither payment model is validated by withdrawal research. Evidence supporting continued clinical attention does not establish that one billing structure is better for you.
Use the first-year cost calculator with complete calendar-month quotes, or the payment calendar tool for fixed-day schedules. Model an early exit as well as continued enrollment. That makes the nonrefundable amount visible before it becomes a reason to delay an appropriate clinical discussion.
Bring a concrete question to the next review
If you are considering stopping, tell the prescribing team why: cost, side effects, a change in goals or a problem obtaining the next supply. Ask what follow-up is needed, who will monitor progress and how to contact the team after a subscription ends. This article supplies no personal taper, dose conversion or restart instruction.
A forced supply gap is a different planning problem from a deliberate clinical change. Read our supply and storage guide when a refill or shipment is uncertain. Contact the prescriber promptly instead of stretching a supply or adopting another patient’s schedule.
The useful purchasing outcome is a service whose ongoing costs and follow-up responsibilities you understand. Return to the provider shortlist with those questions in hand. A believable maintenance discussion should explain the review process and its costs without promising that a trial average predicts your future weight.